Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: Results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers

Baron, 1994, Detection of liver neoplasms: techniques and outcomes, Abdom Imaging, 19, 320, 10.1007/BF00198188

Stark, 1993, Abdominal imaging, JMRI, 3, 285, 10.1002/jmri.1880030140

Schima, 1996, Contrast-enhanced MR imaging, Clin Radiol, 51, 235, 10.1016/S0009-9260(96)80339-4

Saini, 1992, Contrast-enhanced MR imaging of the liver, Radiology, 182, 12, 10.1148/radiology.182.1.1727273

Hamm, 1997, Liver metastases: improved detection with dynamic gadolinium-enhanced MR imaging?, Radiology, 202, 677, 10.1148/radiology.202.3.9051015

Hamm, 1995, Use of contrast agents in the detection and differentiation of focal liver lesions by MR imaging: Gd-DTPA, Mn-DPDP, and iron oxide, 85

Semelka, 1994, Hepatic hemangiomas: a multi-institutional study of appearance of T2-weighted and serial gadolinium-enhanced gradient-echo MR images, Radiology, 192, 401, 10.1148/radiology.192.2.8029404

Mitchell, 1994, Hepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-enhanced MR imaging, Radiology, 193, 49, 10.1148/radiology.193.1.8090921

Powers, 1994, Primary MR liver neoplasms: imaging with pathologic correlation, RadioGraphics, 14, 459, 10.1148/radiographics.14.3.8066263

Hamm, 1994, Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging, Radiology, 190, 417, 10.1148/radiology.190.2.8284392

Mahfouz, 1994, Peripheral washout: a sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions, Radiology, 190, 49, 10.1148/radiology.190.1.8259426

Nakamura, 1994, 3DFT-FISP MRI with gadopentetate dimeglumine in differential diagnosis of small liver tumors, J Comput Assist Tomogr, 18, 49, 10.1097/00004728-199401000-00011

de Haën, 1996, Hepatic transport of gadobenate dimeglumine in TR- rats, Acad Radiol, 3, S452, 10.1016/S1076-6332(96)80614-3

Marzola, 1997, Evaluation of the hepatocyte-specific contrast agent gadobenate dimeglumine for MR imaging of acute hepatitis in a rat model, JMRI, 7, 147, 10.1002/jmri.1880070121

Cavagna, 1994, Binding of gadobenate dimeglumine to proteins extravasated into interstitial space enhances conspicuity of reperfused infarcts, Invest Radiol, 29, S50, 10.1097/00004424-199406001-00018

de Haën, 1993, Soluble-type hepatobiliary contrast agents for MR imaging, JMRI, 3, 179, 10.1002/jmri.1880030130

Cavagna, 1991, Gd-BOPTA/Dimeg: experimental disease imaging, Magn Res Med, 22, 329, 10.1002/mrm.1910220235

Cavagna, 1990, Hepatobiliary contrast agents for magnetic resonance imaging, 384

Cavagna, 1991, Gd-BOPTA/Dimeg: a new hepatobiliary contrast agent for magnetic resonance imaging, 83

Lorusso, 1994, High-performance liquid chromatographic assay of the magnetic resonance imaging contrast agent gadobenate in plasma, urine, and bile, J Chromatogr B, 656, 415, 10.1016/0378-4347(94)80099-5

Shah, 1992, Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies, Pharmaceut Res, 9, 588, 10.1023/A:1015829422034

Lorusso, 1992, Pharmacokinetics and tolerance of Gd-BOPTA/Dimeg (0.25 M) in healthy volunteers (abstr), S18

Pirovano, 1993, Tolerance and pharmacokinetics evaluation of Gd-BOPTA/Dimeg (0.5 M) at high doses in healthy volunteers (abstr), JMRI, 3, 155

Gomeni, 1989

Giovagnoni, 1996, Liver III: gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg), Magn Reson Imaging Clin N Am, 4, 61, 10.1016/S1064-9689(21)00554-7

Rosati, 1994, Interim results of phase II clinical testing of gadobenate dimeglumine, Invest Radiol, 29, S183, 10.1097/00004424-199406001-00060

Weinmann, 1984, Pharmacokinetics of Gd-DTPA/dimeglumine after intravenous injection into healthy volunteers, Physiol Chem Phys Med NMR, 16, 167

McLachlan, 1992, Pharmacokinetic behavior of gadoteidol injection, Invest Radiol, 27, S12